Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage I-IIIa breast cancer~* Postmenopausal or recently postmenopausal~* Recent surgery for breast cancer~* Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status~* No prior treatment with letrozole~Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Metastatic disease~* Invasive bilateral disease~* Clinical or radiological evidence of existing fracture in spine or hip~* Prior treatment with IV bisphosphonates in the past 12 months~* Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)~* Use of Tibolone within 6 months~* Prior use of parathyroid hormone for more than 1 week~* Previous or concomitant malignancy~* Abnormal renal function~* History of disease effecting bone metabolism~Other protocol-defined exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Upfront Zoledronic Acid (Type: EXPERIMENTAL): Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
- Delayed Zoledronic Acid (Type: EXPERIMENTAL): Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).